// App-Quantinova.ai

214 : Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.

Researchers

Presenter

  • Patrick Cotogno

Principal Investigators

  • Elisa M. Ledet

  • Oliver Sartor

  • Allie E. Steinberger

  • Rajasree Pia Chowdry

  • Michael Stolten

Medical Centers

  • Tulane University School of Medicine, New Orleans, LA

  • Tulane Cancer Center, New Orleans, LAOffice of Clinical Research, Tulane Cancer Center, New Orleans, LA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Alpharadin

  • Enzalutamide

  • CB-7598

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved